Valuation: Agios Pharmaceuticals, Inc.

Market Cap 1.65B 1.5B 1.39B 1.26B 2.36B 153B 2.48B 16.86B 6.7B 83.49B 6.19B 6.06B 262B P/E 2026 *
-4.96x
P/E 2027 * -8.9x
Enterprise Value 1.51B 1.38B 1.27B 1.16B 2.17B 140B 2.28B 15.47B 6.15B 76.62B 5.68B 5.56B 240B EV / Sales 2026 *
8.18x
EV / Sales 2027 * 4.68x
Free-Float
77.83%
Yield 2026 *
-
Yield 2027 * -
1 day-4.03%
1 week-12.63%
Current month-9.66%
1 month-24.67%
3 months-17.93%
6 months-3.16%
Current year+1.40%
1 week 27.43
Extreme 27.43
31.7
1 month 27.43
Extreme 27.43
38.69
Current year 24.29
Extreme 24.29
44.09
1 year 24.16
Extreme 24.16
44.09
3 years 20.96
Extreme 20.96
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 08/08/2022
Director of Finance/CFO 51 26/09/2022
Chief Tech/Sci/R&D Officer 47 01/09/2021
Director TitleAgeSince
Director/Board Member 66 09/12/2014
Director/Board Member 73 23/06/2015
Director/Board Member 73 27/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
26/10/26 Exercice

Chief Technology Officer

23,598 0.0395%
22/10/26 Exercice

Chief Technology Officer

1,500 0.0025%
04/08/26 Sell

Chief Technology Officer

-30,000 0.0504%
Change 5-day change 1-year change 3-year change Capi.($)
-4.03%-12.63%+12.33%+28.37% 1.65B
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -1.64%-2.36%+31.53%+160.57% 40B
Weighted average by Cap. -1.49%-1.90%+32.08%+150.39%

Financials

2026 *2027 *
Net sales 185M 169M 155M 141M 265M 17.14B 279M 1.89B 751M 9.36B 695M 680M 29.38B 343M 312M 288M 262M 491M 31.77B 516M 3.5B 1.39B 17.35B 1.29B 1.26B 54.46B
Net income -331M -301M -277M -252M -473M -30.61B -498M -3.38B -1.34B -16.72B -1.24B -1.21B -52.47B -193M -176M -162M -148M -277M -17.9B -291M -1.97B -785M -9.78B -725M -710M -30.68B
Net Debt -136M -124M -114M -104M -195M -12.59B -205M -1.39B -552M -6.87B -510M -499M -21.58B -45.34M -41.3M -38.05M -34.61M -64.94M -4.2B -68.25M -463M -184M -2.29B -170M -167M -7.2B
Projected Income Statement - Annual - Agios Pharmaceuticals, Inc.
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
20/11/26 $27.60 -4.03% 776,195
19/11/26 $28.76 -3.10% 590,439
18/11/26 $29.68 -0.70% 600,084
17/11/26 $29.89 -0.86% 664,573
16/11/26 $30.15 -4.56% 540,855
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Agios Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
27.60USD
Average target price
45.44USD
Spread / Average Target
+64.65%
  1. Stock Market
  2. Stocks
  3. AGIO Stock